Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD)

Autor: Dominik Berliner, Johann Bauersachs, Udo Bavendiek, Hermann Haller, Robert Claus, Michael S. Balzer, Marcus Hiss, Ralf Lichtinghagen, Jean-Marie Launay, Nicolas Vodovar, Sascha David, Margret Patecki
Rok vydání: 2020
Předmět:
Male
medicine.medical_specialty
Growth Differentiation Factor 15
medicine.medical_treatment
030232 urology & nephrology
Chronic kidney disease (CKD)
Growth differentiation factor-15 (GDF-15)
030204 cardiovascular system & hematology
Logistic regression
Peritoneal dialysis (PD)
03 medical and health sciences
0302 clinical medicine
Congestive heart failure (HF)
Predictive Value of Tests
Renal Dialysis
Interquartile range
Internal medicine
Natriuretic Peptide
Brain
medicine
Humans
Protein Precursors
Neprilysin
Neprilysin (NEP)
Dialysis
Retrospective Studies
Heart Failure
Hemodialysis (HD)
Original Paper
Receiver operating characteristic
business.industry
Stroke Volume
Biomarker
General Medicine
Middle Aged
Prognosis
medicine.disease
Peptide Fragments
ROC Curve
Heart failure
Cardiology
Kidney Failure
Chronic
Biomarker (medicine)
Female
GDF15
Cardiology and Cardiovascular Medicine
business
Biomarkers
Follow-Up Studies
Zdroj: Clinical Research in Cardiology
ISSN: 1861-0692
1861-0684
Popis: Background Dialysis patients are at increased risk of HF. However, diagnostic utility of NT-proBNP as a biomarker is decreased in patients on dialysis. GDF-15 and cNEP are biomarkers of distinct mechanisms that may contribute to HF pathophysiology in such cohorts. The aim of this study was to determine whether growth differentiation factor-15 (GDF-15) and circulating neprilysin (cNEP) improve the diagnosis of congestive heart failure (HF) in patients on dialysis. Methods and results We compared circulating concentrations of NT-proBNP, GDF-15, and cNEP along with cNEP activity in patients on chronic dialysis without (n = 80) and with HF (n = 73), as diagnosed by clinical parameters and post-dialysis echocardiography. We used correlation, linear and logistic regression as well as receiver operating characteristic (ROC) analyses. Compared to controls, patients with HF had higher median values of NT-proBNP (16,216 [interquartile range, IQR = 27739] vs. 2883 [5866] pg/mL, p p = 0.014), but not cNEP (315 [107] vs. 318 [124] pg/mL, p = 0.818). Median cNEP activity was significantly lower in HF vs. controls (0.189 [0.223] vs. 0.257 [0.166] nmol/mL/min, p p Conclusion We present novel comparative data on physiologically distinct circulating biomarkers for HF in patients on dialysis. cNEP activity but not concentration and GDF-15 provided incremental diagnostic information over clinical covariates and NT-proBNP and may aid in diagnosing HF in dialysis patients. Graphic abstract
Databáze: OpenAIRE
Externí odkaz: